Avantor, Inc. (AVTR) is a global provider of mission-critical products and services to customers in the life sciences, advanced technologies, and applied materials industries. The company offers a broad portfolio of high-purity materials, laboratory supplies, equipment, and services that enable precise analytical results and support the development and production of life-changing treatments. Avantor's offerings include proprietary brands like J.T.Baker and NuSil, as well as third-party products, serving diverse industries such as biopharma, healthcare, and advanced technologies.
- Laboratory Solutions - Provides products, services, and digital solutions to support research, diagnostics, and quality control workflows. Serves end markets including biopharma, healthcare, education, government, and advanced technologies.
- Bioscience Production - Delivers high-purity materials and solutions for production environments, specializing in bioprocessing, healthcare, and advanced technologies like biologics and semiconductors.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Michael Stubblefield ExecutiveBoard | President and Chief Executive Officer | Michael Stubblefield has been the President and Chief Executive Officer of Avantor, Inc. since 2014. He also serves on Avantor's Board of Directors since May 2014 and joined the Science & Technology Committee in 2025. | View Report → | |
Benoit Gourdier Executive | Executive Vice President, Bioscience Production | Benoit Gourdier is the Executive Vice President, Bioscience Production at AVTR since January 2024. He previously served as Executive Vice President, Biopharma Production from October 2023 to December 2023 and held leadership roles at Merck KGaA. | ||
Brittany Hankamer Executive | Executive Vice President and Chief Human Resources Officer | Brittany Hankamer has been the Executive Vice President and Chief Human Resources Officer at Avantor since August 2023. She previously served as Senior Vice President of Talent and People Operations and Vice President, Human Resources at Avantor. | ||
Christophe Couturier Executive | Executive Vice President, AMEA | Christophe Couturier is the Executive Vice President, AMEA at Avantor since April 2021. He previously served as Executive Vice President, Services from April 2018 to April 2021 and held roles as CEO of Salicornia, LLC and CFO of OvaScience. | ||
Claudius Sokenu Executive | Executive Vice President, Chief Legal and Compliance Officer, and Corporate Secretary | Claudius Sokenu has been serving as the Executive Vice President, Chief Legal and Compliance Officer, and Corporate Secretary at Avantor since July 2023. He has also held significant legal roles at companies like Unisys and Cognizant. | ||
James Bramwell Executive | Executive Vice President, Sales and Customer Excellence | James Bramwell is the Executive Vice President, Sales and Customer Excellence at AVTR since January 2024. He has held several leadership roles at AVTR for over 30 years, including positions as Executive Vice President, Americas and Strategic Partners, demonstrating a strong background in driving the company’s commercial growth. | ||
Kitty Sahin Executive | Executive Vice President, Strategy and Corporate Development | Kitty Sahin is the Executive Vice President, Strategy and Corporate Development at Avantor since June 2022, where she leads strategic initiatives. She previously served as EVP, Strategy & Business Development at Novanta from September 2017 to June 2022. | ||
R. Brent Jones Executive | Executive Vice President and Chief Financial Officer | R. Brent Jones is currently the Executive Vice President and Chief Financial Officer at Avantor since August 7, 2023. He has previously held senior financial roles at LifeScan Global Corporation, Klöckner Pentaplast Group, and Pall Corporation. |
- Based on the Q&A, you mentioned an unexpected pullback in controlled environment consumables demand—what specific initiatives are you employing to drive usage without compromising customer relationships in the long run?
- Your guidance relies on pricing adjustments to offset a 2% COGS tariff exposure, yet tariffs remain highly volatile—how do you plan to implement these price increases without risking customer attrition given the competitive landscape?
- With Lab Solutions under pressure from soft academic and government demand, what concrete actions are being taken to stimulate both capital equipment and consumable sales in these segments and recover lost share?
- In the Bioprocessing segment, lower growth in controlled environment consumables has offset gains in other areas—can you detail the corrective measures you will implement to ensure this lag does not continue to drag down overall performance?
- Amid your CEO transition and the ramp-up of cost transformation initiatives, how will you balance the need for near-term cost reductions with the required investments for long-term strategic growth, and what key performance metrics will guide this process?
Research analysts who have asked questions during Avantor earnings calls.
Daniel Brennan
TD Cowen
6 questions for AVTR
Luke Sergott
Barclays
6 questions for AVTR
Michael Ryskin
Bank of America Merrill Lynch
6 questions for AVTR
Tycho Peterson
Jefferies
6 questions for AVTR
Vijay Kumar
Evercore ISI
6 questions for AVTR
Patrick Donnelly
Citi
5 questions for AVTR
Douglas Schenkel
Wolfe Research, LLC
3 questions for AVTR
Doug Schenkel
Wolfe Research LLC
3 questions for AVTR
Rachel Vatnsdal Olson
JPMorgan
3 questions for AVTR
Tejas Savant
Morgan Stanley
3 questions for AVTR
Conor Noel McNamara
RBC Capital Markets
2 questions for AVTR
Dan Leonard
UBS Group AG
2 questions for AVTR
Brandon Couillard
Wells Fargo & Company
1 question for AVTR
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
1 question for AVTR
Daniel Leonard
Stifel Financial Corp.
1 question for AVTR
Jack Meehan
Nephron Research LLC
1 question for AVTR
Matthew Sykes
Goldman Sachs Group Inc.
1 question for AVTR
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for AVTR
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Masterflex | 2021 | The acquisition was executed as an all‐cash transaction valued at $2.9 billion (net $2.7 billion after tax benefits) with financing through fully committed debt and secondary equity offerings, closing on or about November 1, 2021. The deal strategically strengthens Avantor’s recurring revenue model and single-use platform for high-growth biopharma markets, offering significant cross-selling opportunities in areas like monoclonal antibodies, cell and gene therapies, and COVID-19 production. |
Ritter GmbH | 2021 | Ritter GmbH was acquired via an all-cash transaction with an upfront purchase price of approximately €890 million plus potential €300 million in contingent payments, funded partly through cash on hand and a $1,134.6 million senior secured term loan facility, and was completed on June 10, 2021. This deal expanded Avantor’s high-precision consumables and lab automation portfolio while enhancing its recurring revenue and market presence in biopharma, IVD, and related sectors. |
RIM Bio | 2021 | Completed on June 1, 2021, the acquisition of RIM Bio—a China-based manufacturer of single-use bioprocess bags—was part of Avantor’s strategic expansion in the AMEA region, doubling its cleanroom footprint for single-use manufacturing. Although the financial impact was described as not material, it significantly reduced supply-chain lead times and added critical technology to enhance Avantor’s bioprocessing platform. |
Recent press releases and 8-K filings for AVTR.
- Faruqi & Faruqi, LLP is investigating Avantor, Inc. (AVTR) for alleged federal securities law violations, claiming the company made false and misleading statements about its competitive positioning and failed to disclose negative effects from increased competition.
- The class period for the federal securities class action is from March 5, 2024, to October 28, 2025, with a deadline for investors to seek the role of lead plaintiff by December 29, 2025.
- Key events cited include Avantor's disappointing Q1 2025 financial results, cut guidance, and the stepping down of CEO Michael Stubblefield on April 25, 2025.
- Subsequent events include disappointing Q2 2025 results with a further reduced 2025 guidance (August 1, 2025), and weak Q3 2025 results (October 29, 2025) which included a net loss of $712 million and a $785 million goodwill impairment charge.
- Navantor reported Q3 2025 results, including reported revenue of $1,624 million, a -5% organic growth rate, and adjusted EPS of $0.22.
- The company updated its full-year 2025 guidance, lowering organic revenue growth to -3.5% to -2.5%, adjusted EBITDA margin to mid-16's%, and adjusted EPS to $0.88 to $0.92.
- Navantor authorized a $500 million share repurchase program and achieved 124% free cash flow conversion in Q3 2025.
- The Clinical Services divestiture created headwinds in Q3 2025, including approximately $48 million in reported revenue, $15 million in adjusted EBITDA, and $0.01 in adjusted EPS dilution.
- Avantor reported Q3 2025 revenue of $1.62 billion, a 5% organic year-over-year decline, with adjusted EPS at $0.22 and adjusted EBITDA margin at 16.5%.
- The company updated its full-year 2025 guidance, expecting organic revenue growth of negative 3.5% to negative 2.5% and adjusted EPS between $0.88 and $0.92.
- A $785 million goodwill impairment was recorded for the Lab distribution business due to continued share price weakness and margin headwinds.
- The Board of Directors authorized a $500 million share repurchase program with immediate effect.
- The new CEO, who joined two months prior, introduced the "Avantor Revival" plan to address underperformance and improve operations, focusing on go-to-market strategy, manufacturing investment, portfolio scrutiny, cost savings, and talent.
- Avantor reported Q3 2025 revenue of $1.62 billion, marking a 5% organic decline year-over-year, with adjusted EPS of $0.22 and $172 million in free cash flow.
- The company reduced its full-year 2025 adjusted EPS guidance to a range of $0.88 to $0.92 and now anticipates full-year organic revenue growth of negative 3.5% to negative 2.5%.
- The Board of Directors authorized a $500 million share repurchase program with immediate effect.
- A $785 million non-cash goodwill impairment was recorded for the Lab distribution business, attributed to continued share price weakness and margin headwinds.
- New President and CEO, Emmanuel Ligner, introduced the "Avantor Revival" plan, a five-pillar strategy to address underperformance by focusing on go-to-market, manufacturing investment, portfolio scrutiny, cost savings, and talent improvement.
- New CEO Emmanuel Ligner shared his initial observations after two months, noting the business is overly complex and introduced the "Avantor Revival" plan to address operational and commercial execution challenges.
- The Board of Directors authorized a $500 million share repurchase program with immediate effect, signaling confidence in the company's long-term value.
- Avantor updated its full-year 2025 guidance, now expecting organic revenue growth of negative 3.5% to negative 2.5% and adjusted EPS between $0.88 and $0.92.
- In Q3 2025, Bioscience Production revenue was $527 million, down 4% organically year-over-year, and Laboratory Solutions reported adjusted operating income of $124 million.
- Avantor reported net sales of $1,624 million for Q3 2025.
- The company recorded a GAAP net loss of $712 million and diluted earnings (loss) per share of -$1.04 in Q3 2025, primarily due to $785 million in impairment charges.
- Adjusted net income for Q3 2025 was $151 million , resulting in Adjusted earnings per share of $0.22.
- Adjusted EBITDA reached $268 million with an Adjusted EBITDA margin of 16.5% , while Free Cash Flow was $172 million and Adjusted net leverage stood at 3.1x.
- Core organic growth declined by 4.7% in Q3 2025.
- Avantor, Inc. reported net sales of $1.62 billion for the third fiscal quarter ended September 30, 2025, marking a 5% decrease compared to the prior year period.
- The company recorded a net loss of $712 million and a diluted GAAP loss per share of $1.04, which includes a non-cash goodwill impairment charge of $785 million related to its Distribution reporting unit.
- Avantor achieved adjusted EPS of $0.22 and adjusted EBITDA of $268 million for the quarter.
- The company generated $172 million in free cash flow and announced a $500 million share repurchase authorization.
- Avantor reported net sales of $1.62 billion for the third quarter of 2025, marking a 5% decrease compared to the third quarter of 2024.
- The company posted a net loss of $712 million and a diluted GAAP loss per share of $1.04 for Q3 2025, primarily due to a non-cash goodwill impairment charge of $785 million related to its Distribution reporting unit.
- Adjusted EBITDA for the quarter was $268 million, and adjusted EPS stood at $0.22.
- Avantor generated operating cash flow of $207 million and free cash flow of $172 million during the third quarter of 2025.
- The company's Board of Directors authorized a new $500 million share repurchase program.
- Avantor, Inc. (NYSE: AVTR) has announced a strategic partnership with BlueWhale Bio to advance CAR-T therapy manufacturing.
- The collaboration combines Avantor's bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio's Synecta™ cell-derived nanoparticle (CDNP) platform.
- This partnership aims to accelerate CDNP manufacturing scale-up and produce GMP-grade CDNP materials, addressing critical bottlenecks in CAR-T production by streamlining manufacturing, reducing variability, and shortening time-to-patient.
- On October 9, 2025, Avantor Funding, Inc., a wholly-owned subsidiary of Avantor, Inc., entered into Amendment No. 14 to its Credit Agreement, establishing new credit facilities.
- These new facilities include an aggregate of $1.4 billion in revolving credit commitments (RCF) and new Euro Term Loans consisting of a €400 million tranche of Incremental Euro Term A Loans (TLA) and a €550 million tranche of Incremental B-6 Euro Term Loans (TLB).
- The RCF and TLA mature on October 9, 2030, while the TLB matures on October 9, 2032.
- The proceeds from these new credit facilities will be used to repay and refinance existing senior secured indebtedness, including the A/R Facility and remaining outstanding Notes, and to provide additional liquidity and funding for ongoing business needs.
- Concurrently, on October 9, 2025, the $300 million accounts receivable securitization facility (A/R Facility) was repaid in full and terminated, with $208 million outstanding at the time. The company also completed the redemption of €650 million in aggregate principal amount of its 2.625% Senior First Lien Notes due 2025, with €400 million redeemed on August 29, 2025, and the remaining €250 million redeemed on October 10, 2025.